Arca
Skip to content
Tools
Tools

TNFRSF8: Tumor necrosis factor receptor superfamily member 8

Receptor for TNFSF8/CD30L.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on TNFRSF8, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Antibody-drug conjugate 1
  • Other 2

Approved1

  • Brentuximab vedotin

Phase 31

  • SGN-30

Phase 21

  • Iratumumab

Phase 11

  • HEFI-1

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
Brentuximab vedotinBoxed warningApprovedPfizerAntibody-drug conjugateBinding agentTumor necrosis factor receptor superfamily member 8 binding agent58
SGN-30Phase 3PfizerOtherAgonistTumor necrosis factor receptor superfamily member 8 agonist58
IratumumabPhase 2Bristol-Myers SquibbAntibodyOtherTumor necrosis factor receptor superfamily member 8 other0
HEFI-1Phase 1—OtherBinding agentTumor necrosis factor receptor superfamily member 8 binding agent0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Brentuximab vedotin, SGN-30Phase 2Not yet recruitingPeking University First HospitalJul 21, 2026
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in SpainBrentuximab vedotin, SGN-30—RecruitingGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaJun 3, 2026
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaBrentuximab vedotin, SGN-30Phase 2 / Phase 3Not yet recruitingNational Cancer Institute (NCI)May 7, 2026
BV-CHP Real-life and Biological Evidences in Patients With sALCLBrentuximab vedotin, SGN-30—Not yet recruitingFondazione Italiana Linfomi - ETSMar 12, 2026
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentBrentuximab vedotin, SGN-30Phase 2RecruitingCity of Hope Medical CenterDec 10, 2025
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasBrentuximab vedotin, SGN-30Phase 3Enrolling by invitationN.N. Petrov National Medical Research Center of OncologyDec 2, 2025
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceBrentuximab vedotin, SGN-30Phase 3Not yet recruitingAssistance Publique - Hôpitaux de ParisSep 17, 2025
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ LymphomaBrentuximab vedotin, SGN-30Phase 1 / Phase 2RecruitingChinese PLA General HospitalAug 24, 2025

Diseases most associated with it

Open Targets association score, 0 to 1; all associations
  • Hodgkins lymphoma0.60
  • Respiratory system disorder0.50
  • Allergic disease0.43
  • Deep vein thrombosis0.43
  • Abnormal thrombosis0.43
  • Classic Hodgkin lymphoma0.42
  • Neoplasm0.40
  • Mature T-cell and NK-cell non-Hodgkin lymphoma0.38
  • Atopic asthma0.36

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364161, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P28908, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.